Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3425 - Feasibility and impact of prospective DPYD screening in the Irish population


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Mohammed Zameer


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


M.Z. Zameer1, S. iqbal2, B. macanovic2, D. bracken clarke2, C. joyce2, S. O'Reilly1, R.M. Bambury3, D. Power2, D.C. Collins4

Author affiliations

  • 1 Medical Oncology, Cork University Hospital, 0000 - Cork/IE
  • 2 Medical Oncology, Cork University Hospital, 0000 - cork/IE
  • 3 Medical Oncology, Cork University Hospital, Cork/IE
  • 4 Department Of Medical Oncology, Cork University Hospital, Cork/IE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3425


Genetic variants of dihydropyrimidine dehydrogenase (DPYD) gene can result in varied enzymatic activity and potential toxicity when receiving 5-FU chemotherapy including treatment related death in up to 1% patients. Current international guidelines suggest an international rate of 3-5% albeit routine prospective pharmacogenomic testing is not currently recommended. However, in a genetically homogenous population such as Ireland, DPYD variant enrichment may support routine testing.


All patients receiving 5-FU based chemotherapy in South & South-West region of Ireland were prospectively tested from 01/09/2018 to present. The Viapath DPYD genotyping panel which interrogates for 5 variants was used. Toxicity type and grade for all patients were recorded (CTCAE v5.0).


To date, 139 patients have been tested,50.4% male and 49.6% female, median age 63 years. The majority(59%) were being treated for colorectal cancer. Sixteen patients were found to be heterozygous carriers of a DYPD variant with one compound heterozygous variant identified i.e. an overall prevalence of 12 %. No homozygous carriers were identified. Grade ≥3 was observed in 33% DPYD variant carriers compared to 19% in DPYD wild type patients i.e. relative risk of grade ≥3 toxicity is 1.7, p = 0.17.Table:


DPYD VariantsPrevalence % n = 139% Rate of ≥ G3 toxicity
c. 2846A>T1(0.7%)n/a*
c. 1905 + 1G>A3(2.2%)100%
c. 1679T>G0 (0%)n/a*
c. 1601GA5 (3.6%)0%
c. 1905 + 1G>A+c;1236G>A/Hapb3 compound heterozygous1(0.7%)n/a*
TOTAL:17 (12.2%)


The study shows a higher than expected prevalence of DPYD variants of 12.2% compared to internationally reported 3-5%. Patients with DPYD variants c.1236G>A and c.1905+1G>A were particularly likely to develop Grade ≥ 3 toxicity. Prospective testing continues to assess the clinical relevance of individual variants in our population.

Legal entity responsible for the study: The authors.

Clinical trial identification

Editorial acknowledgement


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.